- Crowds Wire LTD is Launching the Marketing Agency New Site
- Trina Rockstarr "Diamond Princess" Apes into Metaverse with 456 Collectors Club
- Strategic Benefits Advisors, Inc. Data Breach Triggers Investigation into Class Action Lawsuit
"Diarrhea is a common side effect of chemotherapy in dogs, which can be so severe that cancer treatment must be halted. Chemotherapy drugs often have potential side effects, but, unlike in human medicine where patients may be willing to tolerate some discomfort in exchange for a potential cure, the primary purpose of cancer treatment in dogs and other pets is to extend survival without sacrificing quality of life and comfort," said Steven M. Solomon, D.V.M., M.P.H., director of the FDA's Center for Veterinary Medicine. "This new medication provides veterinarians and dog owners with another tool to help control the side effects of chemotherapy for dogs undergoing such treatment."
Canalevia-CA1 is available only by prescription due to the professional veterinary expertise required to properly diagnosis the cause of diarrhea and monitor dogs receiving chemotherapy. Canalevia-CA1 is a tablet that is given by mouth and can be prescribed for home treatment.
The active ingredient in Canalevia-CA1 is crofelemer, which is approved for use in humans to treat non-infectious diarrhea in adults with HIV/AIDS who take anti-retroviral therapy. In humans, crofelemer functions by inhibiting the secretion of chloride ions and water by intestinal epithelial cells, thereby normalizing the gastrointestinal tract. It is thought that the drug functions similarly in dogs.
Canalevia-CA1 received conditional approval through the Minor Use/Minor Species pathway, which is an option for drugs intended for minor uses in major species (dogs, cats, horses, cattle, pigs, turkeys and chickens) or for minor species. Canalevia-CA1 qualified for conditional approval because the FDA estimates that only about 1% of dogs in the U.S. receive a diagnosis of malignant neoplasia (cancer) per year, and not all dogs that receive treatment suffer from chemotherapy-induced diarrhea. Therefore, the agency estimates the rate of occurrence of chemotherapy-induced diarrhea in dogs in the U.S. to be fewer than 70,000 dogs, which qualifies it as a minor use in a major species.
More on Marylandian
- Mr. Ismail Sirdah – A Man Of Intelligence And Patience
- UNDER ARMOUR ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2021 EARNINGS CONFERENCE CALL DATE
- Kaplan Morrell Attorneys at Law Announces New Partner
- Think Systems Announces Promotions and a New Hire Amid Robust Growth
- Culinary And Cannabis Presents The CannaSpa Celebrity Gifting Lounge In Honor of Super Bowl LVI
Conditional approval allows an animal drug sponsor to legally market its product after demonstrating that the drug is safe and manufactured in accordance with full approval standards, and that there is a reasonable expectation of the drug's effectiveness. The initial conditional approval is valid for one year with the potential for four annual renewals. During this time, the animal drug sponsor must demonstrate active progress toward proving substantial evidence of effectiveness for full approval. The animal drug sponsor has five years to obtain full approval after receiving conditional approval, or it will no longer be allowed to be marketed.
The reasonable expectation of effectiveness of Canalevia-CA1 was established in a study with 24 dogs (12 treated and 12 control). A dog was considered a treatment success if its diarrhea resolved and didn't recur during the three-day study. Resolution of diarrhea was defined as a fecal score of one (well-formed stool) or two (soft or very soft, moist stool that doesn't have a clear shape). On the third day, 9 out of 12 dogs (75%) in the treated group were treatment successes compared to 3 out of 12 dogs (25%) in the control group. Additionally, diarrhea had resolved by 48 hours in 4 of the 12 dogs (33%) in the treated group compared to none of the dogs in the control group.
The most common side effects across the laboratory studies and field studies were abnormal feces (soft, watery, mucoid, discolored feces), decreased appetite and activity and vomiting.
Veterinarians should advise owners about the possible side effects before using the drug. The FDA encourages dog owners to work with their veterinary team to report any adverse events or side effects potentially related to the use of any drug, including Canalevia-CA1.
More on Marylandian
- Forced Electrification Could Cost Maryland Consumers More Than $26,000 per Household, New CEA Report Finds
- Console & Associates, P.C. Explores Possible Lawsuits Stemming from Dark Herring Scamware
- Master Magnetics Offers Neodymium Magnets for Sale
- Overstock Kitchen: Your Destination For Cookware To Prepare Your Favorite Homemade Meals
- Gangstagrass Brings Unique Bluegrass Hip-Hop Fusion to Weinberg
The FDA granted conditional approval of Canalevia-CA1 to Jaguar Animal Health.
- Canalevia-CA1 Freedom of Information Summary
- Conditional Approval Explained: A Resource for Veterinarians
- Minor Use/Minor Species
- FDA-TRACK: Center for Veterinary Medicine - Pre-market Animal Drug Review
Media Contact: Veronika Pfaeffle, 310-301-2576 or Kim DiFonzo, 240-651-4191
Veterinary and Consumer Inquiries: [email protected], 800-835-4709
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
SOURCE U.S. Food and Drug Administration
Filed Under: Business
Latest on Marylandian
- CyberSecurity Malaysia, EclecticIQ, and Syntx Sign MOU to Build Cyber Threat Intelligence Capabilities in the Region
- Metavivor Announces Grant Awards For Metastatic Breast Cancer Research
- COPT Sells DC-6 for $222.5 Million
- Commercial Collection Bureau Partners with Leadferno for B2B Text Messaging and More
- 11Sight Welcomes Jason Carver as Vice President of Product Management
- Maxim Biomedical Inc. Receives EUA for New ClearDetect™ COVID-19 Antigen Home Test
- Hutch Incubator Announces a New Cohort of Digital Services Companies
- Meeting Notice: Maryland State Board of Veterinary Medical Examiners Meeting Scheduled for Jan. 27
- Author, Philanthropist, Entrepreneur, And Public Speaker, Mel Jackson To Appear As Keynote Speaker
- Wohler releases iAM-AUDIO-8 with AoIP options
- TRU Staffing Partners Privacy Expert Earns IAPP Certified Information Privacy Manager Credential
- Beacon Healthcare Systems Improves Medicare Application Processing Time by 92%
- THE PENNSYLVANIA HEALTH CARE ASSOCIATION WELCOMES REAL TIME MEDICAL SYSTEMS AS THEIR NEWEST BUSINESS PARTNER
- STS Capital Partners Managing Director Shamil Hargovan Leads 3D Printing Industry Experts Wohlers Associates Sale to ASTM
- Enviva to Hold Conference Call for 2021 Financial Results
- Introducing IDS, a new company from IPD built to revolutionize the connection between owners/operators, assets, and service channels
- Sidow Sobrino's New Song and Music Video Bananas 4 God is Out Now
- 3CLogic Announces Enhanced SMS Capabilities for ServiceNow in Upcoming Spring Release
- Eco-Friendly Legacy Builder Wendy Turner Miller Upends the Waste and Recycling Business with Superior Innovative Solutions, LLC
- OpsVeda Announces Completion Of SOC 2 Type II Certification